1. Mima A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages. Eur J Pharmacol. 2021 Dec 5;912:174583. doi: 10.1016/j.ejphar.2021.174583. Epub 2021 Oct 19. PMID: 34678238.
2. Hu X, Xie J, Chen N. Hypoxia-Inducible Factor-Proline Hydroxylase Inhibitor in the Treatment of Renal Anemia. Kidney Dis 2021;7:1–9. DOI: 10.1159/000510587
3. Eriksson D, Goldsmith D, Teitsson S, Jackson J, van Nooten F. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol. 2016; 17(1): 97. doi: 10.1186/s12882-016-0312-9.
4. Kaplan JM, Sharma N, Dikdan S. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. Int. J. Mol. Sci. 2018, 19, 389; doi:10.3390/ijms19020389
5. Gupta N, Wish J. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis. 2017;69(6):815-826. doi: 10.1053/j.ajkd.2016.12.011
6. Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2016;12(3):157-68. doi: 10.1038/nrneph.2015.193.
7. Coyne DW, Goldsmith D, Macdougall LC. New options for the anemia of chronic kidney disease. Kidney International Supplements, 2017. 7, 157–163. DOI: https://doi.org/10.1016/j.kisu.2017.09.002
8. Zuo L, Wang M, Hou F, Yan Y, Chen N, Qian J, et al. Anemia management in the China dialysis outcomes and practice patterns study. Blood Purif. 2016; 42(1): 33–43. Doi: 10.1159/000442741.
9. Kurata Y, Tanaka T, Nangaku M. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens. 2020 Jul;29(4):414-422. doi: 10.1097/MNH.0000000000000617. PMID: 32452915.
10. Chen N, Qian J, Chen J, Yu X, Mei C, Hao C, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017; 32(8): 1373-1386. Doi: 10.1093/ndt/gfx011.
11. Akizawa T, Iwasaki M, Otsuka T, Reusch M, Misumi T. Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Adv Ther. 2019; 36(6): 1438–54. Doi: 10.1007/s12325-019-00943-4.
12. Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, et al. Fourweek studies of oral hypoxia-inducible factorprolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016. Apr; 27(4): 1234–44. DOI: https://doi.org/10.1681/ASN.2014111139
13. Akizawa T, Tsubakihara Y, Nangaku M, Endo Y, Nakajima H, Kohno T, et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol. 2017; 45(2): 127–35. Doi: 10.1159/000454818.
14. Brigandi RA, Johnson B, Oei C, Westerman M, Olbina G, de Zoysa J, et al. A novel hypoxia- inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28- day, phase 2A randomized trial. Am J Kidney Dis. 2016 Jun; 67(6): 861–71. Doi: 10.1053/j.ajkd.2015.11.021.
15. Cizman B, Sykes AP, Paul G, Zeig S, Cobitz AR. An exploratory study of daprodustat in erythropoietin-hyporesponsive subjects. Kidney Int Rep. 2018 Jul; 3(4): 841–50. Doi: 10.1016/j.ekir.2018.02.009.
16. Meadowcroft AM, Cizman B, Holdstock L, Biswas N, Johnson BM, Jones D, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J. 2019 Feb; 12(1):139–48. Doi: 10.1093/ckj/sfy014.
17. Singh AK, et al. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med 2021; 385:2313-2324 DOI: 10.1056/NEJMoa2113380
18. Singh AK, et al. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med 2021; 385:2325-2335 DOI: 10.1056/NEJMoa2113379
19. Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T. Effects of Molidustat in the treatment of anemia in CKD. Clin J Am Soc Nephrol. 2019 Jan 7; 14(1): 28–39. Doi: 10.2215/CJN.02510128.
20. Akizawa T, Macdougall IC, Berns JS, Yamamoto H, Taguchi M, Iekushi K, et al. Iron regulation by Molidustat, a daily oral hypoxiainducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron. 2019; 143(4): 243–54. Doi: 10.1159/000502012.
21. Yamamoto H, et al. Efficacy and Safety of Molidustat for Anemia in ESA-Naïve Nondialysis Patients: A randomized, Phase 3 Trial. AM J nephrol 2021;52:871-883. https://doi.org/10.1159/000518071
22. Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016 Nov; 90(5): 1115–22. Doi: 10.1016/j.kint.2016.07.019.
23. Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM. Clinical trial of Vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol. 2017; 45(5): 380–8. Doi: 10.1159/000464476.
24. Haase VH, Chertow GM, Block GA, Pergola PE, deGoma EM, Khawaja Z, et al. Effects of Vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2019 Jan 1;34(1): 90–9. Doi: 10.1093/ndt/gfy055.
25. Nangaku M, et al. Efficacy and Safety of vadadustat compared with darbepoietin alfa in Japanese anemic patientson hemodialysis: a Phase 3, multicenter, randomized, double blind study. Nephrol Dial Transplant, 2021. 36: 1731–1741 DOI: 10.1093/ndt/gfab055.
26. Eckardt KU, et al. Safety and Efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med 2021; 384:1601-1612 DOI: 10.1056/NEJMoa2025956
27. Chertow GM, et al. Vadadustat in patients with anemia and Non-dialysis Dependent CKD. N Engl J Med 2021; 384:1589-1600 DOI: 10.1056/NEJMoa2035938
Facebook 
Masuk dengan Email
